Abstract:>90% of genes in the human body undergo alternative splicing (AS) after transcription, which enriches protein species and regulates protein levels. However, there is growing evidence that various genetic isoforms resulting from dysregulated alternative splicing are prevalent in various types of cancers. Dysregulated alternative splicing leads to cancer generation and maintenance of cancer properties such as proliferation differentiation, apoptosis inhibition, invasion metastasis, and angiogenesis. Serine/arginine-rich proteins and SR protein-associated kinases mediate splice site recognition and splice complex assembly during variable splicing. Based on the impact of dysregulated alternative splicing on disease onset and progression, the search for small molecule inhibitors targeting alternative splicing is imminent. In this review, we discuss the structure and specific biological functions of SR proteins and describe the regulation of SR protein function by SR protein related kinases meticulously, which are closely related to the occurrence and development of various types of cancers. On this basis, we summarize the reported small molecule inhibitors targeting SR proteins and SR protein related kinases from the perspective of medicinal chemistry. We mainly categorize small molecule inhibitors from four aspects, including targeting SR proteins, targeting Serine/arginine-rich protein-specific kinases (SRPKs), targeting Cdc2-like kinases (CLKs) and targeting dual-specificity tyrosine-regulated kinases (DYRKs), in terms of structure, inhibition target, specific mechanism of action, biological activity, and applicable diseases. With this review, we are expected to provide a timely summary of recent advances in alternative splicing regulated by kinases and a preliminary introduction to relevant small molecule inhibitors.

A Critical Update on the Strategies Towards Small Molecule Inhibitors Targeting Serine/arginine-rich (SR) Proteins and Serine/arginine-rich Proteins Related Kinases in Alternative Splicing

Targeting Serine- and Arginine-Rich Splicing Factors to Rectify Aberrant Alternative Splicing.

SR proteins in cancer: function, regulation, and small inhibitor

Alternative splicing and cancer: a systematic review

Towards Understandings of Serine/arginine-Rich Splicing Factors

SR Splicing Factors Promote Cancer Via Multiple Regulatory Mechanisms.

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Targeting splicing factors for cancer therapy

Alternative splicing and related RNA binding proteins in human health and disease

Serine-arginine protein kinases and their targets in viral infection and their inhibition

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

Therapeutic strategies for aberrant splicing in cancer and genetic disorders

Targeting Splicing Factor SRSF6 for Cancer Therapy

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

Significance of Alternative Splicing in Cancer Cells.

Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives

The role of alternative pre-mRNA splicing in cancer progression

RNA splicing dysregulation and the hallmarks of cancer

Splicing Dysregulation in Cancer: from Mechanistic Understanding to a New Class of Therapeutic Targets

Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing